Skip to the page

Data / Drug companies / Catalent Pharma Solutions, LLC

Catalent Pharma Solutions, LLC: 273 products in the FDA NDC directory, labeler code 11014

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Catalent Pharma Solutions, LLC (labeler code 11014) lists 273 products in the FDA National Drug Code Directory. By type: 273 drugs for further processing. Its main marketing category is drugs for further processing. The newest product started marketing on September 11, 2026.

The request: Watch Catalent Pharma Solutions, LLC (FDA labeler code 11014): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
11014
Products in commercial distribution
273
Packages
295
Finished drugs by generic name
0
Prescription products
0
Over the counter products
0
Controlled substance products
Schedule II 16, Schedule III 7, Schedule IV 16, Schedule V 3
Started marketing in the last 12 months
7
Products with a marketing end date set
10
Earliest marketing start
February 10, 1958
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Drugs for further processing24087.9%
Export only3312.1%

Products by type

TypeProductsShare
Drugs for further processing273100%

Dosage forms

Dosage formProductsShare
Capsule12044%
Tablet, film coated3412.5%
Capsule, liquid filled3111.4%
Capsule, extended release3111.4%
Tablet197%
Capsule, gelatin coated93.3%
Insert51.8%
For suspension, extended release41.5%
Lozenge41.5%
Spray41.5%
Powder31.1%
Injection, solution20.7%

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Apitegromab11014-0769Injection, solutionDrugs for further processingSeptember 11, 2026
Lunsotogene parvec11014-0768Injection, solutionDrugs for further processingApril 23, 2026
Ensitrelvir11014-0763TabletDrugs for further processingApril 16, 2026
Selinexor11014-0767Tablet, film coatedDrugs for further processingJanuary 5, 2026
Etripamil11014-0766SprayDrugs for further processingJanuary 5, 2026
Sodium oxybate11014-0764For suspension, extended releaseDrugs for further processingJanuary 1, 2026
Hydrocortisone11014-0765CapsuleExport onlyDecember 8, 2025
Levodopa11014-0733CapsuleExport onlySeptember 30, 2025
Suzetrigine11014-0753Tablet, film coatedDrugs for further processingAugust 18, 2025
Relacorilant11014-0734CapsuleDrugs for further processingAugust 4, 2025
Pralsetinib11014-0740CapsuleDrugs for further processingJuly 30, 2025
Sebetralstat11014-0730Tablet, film coatedDrugs for further processingJuly 4, 2025
Zanubrutinib11014-0719Tablet, film coatedDrugs for further processingApril 12, 2025
Selinexor11014-0729Tablet, film coatedDrugs for further processingMarch 10, 2025
Crinecerfont11014-0681CapsuleDrugs for further processingFebruary 28, 2025
Omega-3-acid ethyl esters11014-0710Capsule, liquid filledDrugs for further processingFebruary 27, 2025
Suzetrigine11014-0728Tablet, film coatedDrugs for further processingFebruary 14, 2025
Relacorilant11014-0711CapsuleDrugs for further processingFebruary 11, 2025
Nicotine11014-0743LozengeDrugs for further processingFebruary 3, 2025
Nicotine11014-0742LozengeDrugs for further processingFebruary 1, 2025
Nicotine11014-0745LozengeDrugs for further processingJanuary 1, 2025
Nicotine11014-0744LozengeDrugs for further processingJanuary 1, 2025
Xanomeline and trospium chloride11014-0725CapsuleDrugs for further processingDecember 10, 2024
Xanomeline and trospium chloride11014-0724CapsuleDrugs for further processingNovember 27, 2024
Xanomeline and trospium chloride11014-0723CapsuleDrugs for further processingNovember 22, 2024

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.